Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
9/5/24 | Crestone | CRS3123 for Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI) | Subscribers Only | Subscribers Only | Subscribers Only |
9/3/24 | Athira Pharma (ATHA) | ATH-1017 for Alzheimer's Disease (AD) | Subscribers Only | Subscribers Only | Subscribers Only |
9/3/24 | Praxis (PRAX) | Relutrigine for Seizure Disorders (Epilepsy) | Subscribers Only | Subscribers Only | Subscribers Only |
9/2/24 | Sanofi (SNY) | SAR442168 for Multiple Sclerosis (MS) | Subscribers Only | Subscribers Only | Subscribers Only |
8/31/24 | George Medicines | GMRx2 for Hypertension (Systemic) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
01/01/25 - 04/30/24 | Subscribers Only | Subscribers Only | Progress Update - Product Launch |
07/31/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
09/09/24 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
09/09/24 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
09/09/24 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |